央视网消息：据"生态环境部"微信公众号消息，第三轮第四批中央生态环境保护督察是《生态环境保护督察工作条例》印发实施后的首批督察。各督察组深 入贯彻落实习近平生态文明思想和习近平总书记重要指示批示精神，统筹开展流域督察和省域督察，既关注黄河流域生态保护和高质量发展政策衔接、区域 协调、机制建设等流域性、整体性、共性问题，也注重结合各省（区）经济社会发展、自然资源禀赋、生态安全定位，找准各省（区）突出问题，深入一 线、深入现场，查实了一批突出生态环境问题，核实了一批不作为、慢作为，不担当、不碰硬，甚至敷衍应对、弄虚作假等形式主义、官僚主义问题。为发 挥警示作用，切实推动问题整改，现对第一批典型案例进行集中公开通报。 典型案例 | 山西省晋中吕梁等市违规取水用水问题多发 2025年5月，中央第一生态环境保护督察组督察山西省发现，晋中、吕梁等市落实以水定城、以水定地、以水定人、以水定产要求不到位，存在违规取水、 水源置换工程推进不力、地下水压采工作不严不实等问题。 一、基本情况 《中华人民共和国黄河保护法》规定，水资源超载地区县级以上地方人民政府应当制定水资源超载治理方案，采取产业结构调整、强化节水等措施，实施综 合 ...

Core Insights - Candel Therapeutics has appointed Dr. Maha Radhakrishnan to its Board of Directors, effective June 4, 2025, to enhance its strategic capabilities as it moves towards Biologics License Application (BLA) submission and commercial development [1][2][4] Company Overview - Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies aimed at treating cancer [5] - The company has two clinical-stage platforms based on genetically modified adenovirus and herpes simplex virus (HSV) gene constructs [5] Product Development - Candel's lead product candidate, CAN-2409, is being developed for intermediate-to-high-risk prostate cancer, with BLA submission anticipated in Q4 2026 [2][4] - Recent successful phase 2a clinical trials of CAN-2409 were completed in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) [6] - CAN-2409 has received Fast Track Designation from the FDA for treating PDAC and stage III/IV NSCLC in specific patient populations [6] Leadership Experience - Dr. Radhakrishnan brings over 20 years of experience in product development and commercialization from major biotechnology and pharmaceutical companies [3] - Her previous roles include Senior Vice President and Chief Medical Officer at Biogen and Global Head of Medical at Sanofi [3] Future Outlook - The company aims to leverage Dr. Radhakrishnan's expertise as it prepares for the BLA submission and advances its innovative immunotherapy candidates [2][4]

Market Overview - The Asia-Pacific Pharmaceutical Contract Manufacturing Organization (CMO) Market is projected to grow from an estimated USD 59.97 billion in 2025 to USD 91.18 billion by 2030, reflecting a compound annual growth rate (CAGR) of 8.74% [2] - The market landscape is highly fragmented, with large pharmaceutical firms increasingly outsourcing production to CMOs for cost efficiency and expertise [6] Regional Insights - China's competitive advantage in the CMO market is attributed to low labor costs, tax incentives, and favorable currency valuation, which help reduce manufacturing expenses [3] - India is attracting Japanese pharmaceutical investments through favorable foreign direct investment policies, enhancing its domestic manufacturing landscape [8] - Japan's CMO sector has experienced a 30% growth due to regulatory changes that separate manufacturing from sales [8] - Australia faces challenges due to pricing and reimbursement volatility but benefits from its geographical proximity to South Asian markets [8] Market Dynamics - The demand for injectable drugs, particularly for rapid-acting oncology treatments, presents significant growth opportunities within the market [8] - Prolific late-stage clinical trials, especially in cancer therapies, are expected to drive market growth, with anti-cancer drugs making up nearly half of the developmental pipeline [8] - Outsourcing of biologic formulations to CMOs is common as major pharmaceutical companies focus on discovering and developing new drug modalities [8] Industry Developments - Recent expansions by companies such as Jubilant Biosys in India and Boehringer's capacity increase in China highlight strategic collaborations aimed at enhancing market share [6] - New policies in India allowing certain drug studies without late-stage clinical trials lead to considerable cost savings, further strengthening its appeal for pharmaceutical production [8] Challenges - The COVID-19 pandemic has disrupted global supply chains, necessitating strategic responses to inventory management, particularly as China is a key supplier of essential raw materials [8] - Increasing lead times and logistics costs, along with stringent regulatory requirements, pose challenges for the CMO market [14]

《西安市支持科技企业提质增效实施方案（2025—2027年）》印发 以更大力度推动西安区域科技创新中心建设 近日，西安市人民政府办公厅印发《西安市支持科技企业提质增效实施方案（2025—2027年）》 （以下简称《方案》），以持续强化企业科技创新主体地位，提升科技企业创新引领力和竞争力，推动 科技服务业支撑新质生产力发展。 《方案》聚焦西安区域科技创新中心建设任务，明确到2027年西安市将实现高新技术企业超过1.8 万家（其中，规模以上企业超过3200家），营收总额达到1.5万亿元；瞪羚企业超过1200家；企业研发 投入经费占全社会研发投入经费比例达到55%；全市技术合同成交额达到5600亿元。 推进科技型企业量质双升。西安市将支持企业强化创新能力建设，加快成长为高新技术企业；支持 企业开发新产品，提供新服务，塑造发展优势；加快科技服务业企业"小升规"，支持龙头骨干企业纳入 科技领军（潜力）企业名录。 提升科技企业创新能力。西安市将鼓励规上企业建设研发机构，持续加大研发投入；支持有条件的 企业布局建设工程技术研究中心和技术创新中心，提升源头创新能力；引导龙头骨干企业布局建设高质 量孵化载体。 加强重点领域技术 ...

Emergent BioSolutions (EBS) 2025 Conference June 05, 2025 01:25 PM ET Speaker0 Okay. Speaker1 Good afternoon, and welcome to the Jefferies Global Healthcare Conference. My name is Victoria Gendron with the Jefferies Investment Banking Team, and it is with my great pleasure to introduce Richard Lindahl, the CFO of Emergent BioSolutions. Speaker0 Okay. Thank you very much, Victoria, and, thank you all for coming today. We appreciate your interest in our company. I'm going to start, with the standard safe harb ...

Top three teams recognized for ideas to create sustainable electric mobility, tumor diagnostics accuracy and remote neurological monitoring BENGALURU, India, and BLUE BELL, Pa., June 5, 2025 /PRNewswire/ -- Unisys (NYSE: UIS) is pleased to announce the winners of the 16th iteration of the Unisys Innovation Program (UIP), a competition for engineering students across India. Established in 2009, the program bridges the gap between academic learning and hands-on experience by bringing young engineers together ...

Stevanato Group (STVN) 2025 Conference June 05, 2025 10:30 AM ET Speaker0 Jeff there we go. Hi. Good morning. Dave Windley with Jefferies Healthcare Equity Research. Appreciate your attendance and and interest in our conference twenty twenty five. We are on kind of the homestretch here on Thursday. Our presenting company for this session is Stevanato Group. Here to present for them is the company's CEO, Franco Sveinato. So he has just a few slides and is going to give some prepared remarks to kick off and t ...

Kodiak Sciences (KOD) 2025 Conference June 05, 2025 09:20 AM ET Speaker0 Here in New York. So Yeah. Here in New York. So it's good to be back here looking at the the summer. So we're close to midyear twenty twenty five. And at Kodiak, we have been very busy, and we have a number of activities in progress and a number of activities in in preparation. So it's an exciting time for Kodiak. It's exciting time, I think, for people to to look at us and to think about what our potential is As a company, we, of cour ...

BRISBANE, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami Beach, FL from June 9 – 11, 2025. The management team will also participate i ...

On Tuesday, Zydus Lifesciences Ltd. announced its entry into the global biologics contract development and manufacturing organization (CDMO) business through its plan to acquire Agenus Inc.’s AGEN U.S.-based biologics CMC facilities.The acquisition marks Zydus’ strategic investment in U.S.-based biologics manufacturing, thereby adding a sustainable growth driver for the group.Agenus is a clinical-stage immuno-oncology company.Zydus will acquire two biologics manufacturing facilities from Agenus in Emeryvill ...